Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
IPO Year: 2013
Exchange: NASDAQ
Website: veracyte.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/23/2024 | $30.00 → $33.00 | Buy | Needham |
1/18/2023 | Outperform → Mkt Perform | Raymond James | |
1/5/2023 | $33.00 | Sector Outperform | Scotiabank |
3/2/2022 | $52.00 → $44.00 | Overweight | Stephens & Co. |
3/1/2022 | $62.00 → $34.00 | Outperform | Raymond James |
3/1/2022 | $45.00 → $40.00 | Outperform | SVB Leerink |
1/7/2022 | $52.00 | Overweight | Stephens & Co. |
11/18/2021 | $60.00 | Buy | Goldman |
11/10/2021 | $50.00 → $62.00 | Outperform | Raymond James |
7/30/2021 | $45.00 → $42.00 | Underweight | Morgan Stanley |
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower cli
Award marks company's 11th consecutive year of receiving this honor Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle. The award marks the 11th consecutive year that Veracyte has received this honor. The Bay Area Top Workplace award winners are determined based solely on employee feedback gathered by Energage, an employee engagement technology partner. The firm administers a confidential survey that measures employee experience and its component themes, including the degree to which employees feel respected and supported, enabled to grow and empowered to execute, among others
Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief executive officer. "With both tests clearly gaining share in their respective markets and plenty of headroom for durable future expansion, our confidence in their long-term prospects continues to grow. Meanwhile, our positive cash generation and class-leading profitability profile are fueling a portf
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conferen
Findings presented at the ENDO 2024 conference Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize care based on each patient's tumor biology, are derived from research using Veracyte's Afirma GRID (Genomic Resource for Intelligent Discovery) tool. The results were presented today at ENDO 2024, the annual meeting of The Endocrine Society in Boston. "Clinicians generally want to avoid overtreatment of patients with non-aggress
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help to further personalize treatment of the disease. The findings will be presented at ENDO 2024, the annual meeting of The Endocrine Society, which will take place June 1-4 in Boston. "Molecular testing in thyroid cancer currently focuses primarily on whether a patient's thyroid nodule is benign or cancerous, and whether specific gene mutations are present," said Joshua Klopper, M.D., Veracyte's medical
Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences. Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX Fireside Chat on May 29th at 12:20 p.m. Eastern Time William Blair 44th Annual Growth Stock Conference – Chicago, IL Presentation on June 4th at 5:40 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available following the conclusion of the live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global
Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the first quarter ended March 31, 2024. "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone," said Marc Stapley, Veracyte's chief executive officer. "We also expanded our capabilities into minimal residu
Large number of abstracts also showcases power of the Veracyte Diagnostics Platform Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches. They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases. The findings were presented during the conference taking place
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
4 - VERACYTE, INC. (0001384101) (Issuer)
3 - VERACYTE, INC. (0001384101) (Issuer)
3 - VERACYTE, INC. (0001384101) (Issuer)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
SC 13G/A - VERACYTE, INC. (0001384101) (Subject)
8-K - VERACYTE, INC. (0001384101) (Filer)
144 - VERACYTE, INC. (0001384101) (Subject)
10-Q - VERACYTE, INC. (0001384101) (Filer)
8-K - VERACYTE, INC. (0001384101) (Filer)
144 - VERACYTE, INC. (0001384101) (Subject)
8-K - VERACYTE, INC. (0001384101) (Filer)
S-8 - VERACYTE, INC. (0001384101) (Filer)
144 - VERACYTE, INC. (0001384101) (Subject)
144 - VERACYTE, INC. (0001384101) (Subject)
10-Q - VERACYTE, INC. (0001384101) (Filer)
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio. The HOOD Trade: Ark Invest’s decision to trim its position in Robinhood was executed through three of its ETFs. The ARK Fintech Innovation ETF (NYSE:ARKF) sold 31,827 shares, while the ARK Innovation ETF (NYSE:ARKK) and the ARK Next Generation Internet ETF (NYSE:ARKW) offloaded 215,675 and 76,299 shares respectively. Based on Robinhood’s closing price of $23.42 on Monday, the total value of the shares sold is approximately $7.6 mill
4 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 0 0 1 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 1 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.25, with a high estimate of $33.00 and a low estimate of $21.00. A negative shift in sentiment is eviden
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $33 to $27.
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.24 percent. This is a 81.82 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $96.844 million which beat the analyst consensus estimate of $93.370 million by 3.72 percent. This is a 17.50 percent increase over sales of $82.422 million the same period last year.
Large number of abstracts also showcases power of the Veracyte Diagnostics PlatformVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches. They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases. The findings were presented during the conference taking place May
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress. The findings make the Decipher test the only gene expression test to have treatment-outcome data from a prospective, multi-center, phase 2, randomized trial in the AS population.Patients whose prostate cancer is found at an early stage and who are clinically low or intermediate risk are commonly offered AS, meaning they are closely monitored rather than undergo i
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio. Studies to be presented include those that evaluate the clinical utility of the company's Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers' underlying biology, which researchers derived through use of Veracyte's whole-transcriptome-based Decipher GRID research tool."The data being prese
Goldman Sachs analyst Matthew Sykes maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $32 to $28.
Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the second quarter ended June 30, 2024. "Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma," said Marc Stapley, Veracyte's chief executive officer. "With both tests clearly gaining share in their respective markets and plenty of headroom for durable future expansion, our confidence in their long-term prospects continues to grow. Meanwhile, our positive cash generation and class-leading profitability profile are fueling a portf
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/p5tuszv4. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conferen
Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the first quarter ended March 31, 2024. "We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We executed upon our strategies to further penetrate these markets by expanding our clinical evidence, and, for Decipher, securing enhanced status in guidelines while also achieving a key commercial reimbursement milestone," said Marc Stapley, Veracyte's chief executive officer. "We also expanded our capabilities into minimal residu
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/6m9ec99y. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conference c
Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. "We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses," said Marc Stapley, Veracyte's chief executive officer. "Looking to 2024 and beyond, we will leverage our Veracyte Diagnostics Platform to continue to drive near- and long-term revenue. With multiple growth catalysts over the coming years and with our strong financial discipline, we expect to achieve positive cash
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/tkiac6t9. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations.
Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the third quarter ended September 30, 2023. "I am pleased to share we delivered another quarter of strong revenue growth, fueled by continued demand for our Decipher Prostate and Afirma tests," said Marc Stapley, Veracyte's chief executive officer. "These products are serving a critical unmet need for patients dealing with prostate and thyroid cancer, indications for which we believe there remains ample opportunity to fuel outsized, long-term growth." Key Business Highlights Increas
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, November 7, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/e88ivgzk. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The confere
Grew Total Revenue to $90.3 million, an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the second quarter ended June 30, 2023. "We delivered outstanding second quarter results, with revenue and test volume that exceeded our expectations. We also generated a record $17 million in cash from operations this quarter, driven by our exceptional top-line performance and strong cash collections," said Marc Stapley, Veracyte's chief executive officer. "The compelling clinical data we shared this quarter demonstrates our focus on producing further evidence that our tests are helping to better guide patient car
Veracyte, Inc. (NASDAQ:VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/iwy5xkbf. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations. The conferen
Needham reiterated coverage of Veracyte with a rating of Buy and set a new price target of $33.00 from $30.00 previously
Raymond James downgraded Veracyte from Outperform to Mkt Perform
Scotiabank initiated coverage of Veracyte with a rating of Sector Outperform and set a new price target of $33.00
Stephens & Co. reiterated coverage of Veracyte with a rating of Overweight and set a new price target of $44.00 from $52.00 previously
Raymond James reiterated coverage of Veracyte with a rating of Outperform and set a new price target of $34.00 from $62.00 previously
SVB Leerink reiterated coverage of Veracyte with a rating of Outperform and set a new price target of $40.00 from $45.00 previously
Stephens & Co. initiated coverage of Veracyte with a rating of Overweight and set a new price target of $52.00
Goldman resumed coverage of Veracyte with a rating of Buy and set a new price target of $60.00
Raymond James reiterated coverage of Veracyte with a rating of Outperform and set a new price target of $62.00 from $50.00 previously
Morgan Stanley reiterated coverage of Veracyte with a rating of Underweight and set a new price target of $42.00 from $45.00 previously
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac
Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a
Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company's legal functions and will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220228005304/en/Veracyte Appoints Annie McGuire as General Counsel (Photo: Business Wire) "We are delighted to welcome Annie to Veracyte," said Mr. Stapley. "She brings with her significant experience in Fortune 100 and other healthcare companies. Her proven leadership
Veracyte, Inc. (NASDAQ:VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company's global accounting operations, financial reporting and tax functions. He will report to Rebecca Chambers, Veracyte's chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220222005393/en/Veracyte Appoints Jonathan Wygant as Chief Accounting Officer (Photo: Business Wire) "We are thrilled to welcome Jonathan to Veracyte," said Ms. Chambers. "He brings a depth of expertise and experience leading acco
Veracyte, Inc. (NASDAQ:VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Richard T. Kloos, M.D., Veracyte's executive medical director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005316/en/Joshua Klopper, M.D. (Photo: Business Wire) "Dr. Klopper is an exceptional addition to Veracyte's world-class medical team," said Dr. Kloos. "He was an investigator
Veracyte, Inc. (NASDAQ:VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers, a seasoned financial executive with a track record for scaling high-growth healthcare businesses, will join the company July 19, reporting to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210712005237/en/Rebecca Chambers has been appointed EVP and Chief Financial Officer of Veracyte. (Photo: Business Wire) "We believe that our recent acquisitions and strategic initiatives have put in place th
Keith Kennedy will retire following Q1 earnings release and 10-Q; Jane Alley appointed as acting CFO; Veracyte to conduct CFO search Veracyte, Inc. (NASDAQ:VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May 15, 2021, following the company's release of its full quarterly financial results and the filing of its Form 10-Q for the first quarter 2021. Jane Alley, vice president and corporate controller, will become acting CFO until a replacement is named. Veracyte is conducting a search for a new CFO. "Keith has played a key role in Veracyte's growth and success over the last four years and the board and I deeply
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately. “We are thrilled to welcome Muna Bhanji to our board,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “She is a healthcare industry veteran with a distinguished career of driving successful commercialization and market access strategies across a range of products in global markets. Her guidance will be instrumental as we expand our global footprint with a growing menu of advanced genomic tests that impr